Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EXOC4_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EXOC4_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EXOC4_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/EXOC4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EXOC4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/EXOC4_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EXOC4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EXOC4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EXOC4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EXOC4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EXOC4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EXOC4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000170411 | Prostate | Tumor | formation of primary germ layer | 36/3246 | 121/18723 | 5.22e-04 | 3.82e-03 | 36 |
GO:002240612 | Prostate | Tumor | membrane docking | 26/3246 | 86/18723 | 2.29e-03 | 1.29e-02 | 26 |
GO:000690313 | Prostate | Tumor | vesicle targeting | 16/3246 | 45/18723 | 2.59e-03 | 1.43e-02 | 16 |
GO:000689313 | Prostate | Tumor | Golgi to plasma membrane transport | 19/3246 | 60/18723 | 4.84e-03 | 2.37e-02 | 19 |
GO:00073699 | Skin | AK | gastrulation | 41/1910 | 185/18723 | 1.32e-06 | 4.13e-05 | 41 |
GO:00017045 | Skin | AK | formation of primary germ layer | 30/1910 | 121/18723 | 3.12e-06 | 8.17e-05 | 30 |
GO:005165618 | Skin | AK | establishment of organelle localization | 69/1910 | 390/18723 | 3.69e-06 | 9.11e-05 | 69 |
GO:00604857 | Skin | AK | mesenchyme development | 48/1910 | 291/18723 | 5.64e-04 | 5.06e-03 | 48 |
GO:001050618 | Skin | AK | regulation of autophagy | 51/1910 | 317/18723 | 6.97e-04 | 5.96e-03 | 51 |
GO:0007498 | Skin | AK | mesoderm development | 25/1910 | 129/18723 | 1.21e-03 | 9.28e-03 | 25 |
GO:004819319 | Skin | AK | Golgi vesicle transport | 47/1910 | 296/18723 | 1.46e-03 | 1.06e-02 | 47 |
GO:005165017 | Skin | AK | establishment of vesicle localization | 28/1910 | 161/18723 | 3.44e-03 | 2.09e-02 | 28 |
GO:000689216 | Skin | AK | post-Golgi vesicle-mediated transport | 20/1910 | 104/18723 | 3.91e-03 | 2.30e-02 | 20 |
GO:000689310 | Skin | AK | Golgi to plasma membrane transport | 13/1910 | 60/18723 | 6.62e-03 | 3.50e-02 | 13 |
GO:00483321 | Skin | AK | mesoderm morphogenesis | 15/1910 | 74/18723 | 7.07e-03 | 3.63e-02 | 15 |
GO:001623618 | Skin | AK | macroautophagy | 43/1910 | 291/18723 | 8.39e-03 | 4.16e-02 | 43 |
GO:009887616 | Skin | AK | vesicle-mediated transport to the plasma membrane | 23/1910 | 136/18723 | 1.05e-02 | 4.96e-02 | 23 |
GO:000736914 | Skin | SCCIS | gastrulation | 24/919 | 185/18723 | 1.33e-05 | 4.40e-04 | 24 |
GO:000170413 | Skin | SCCIS | formation of primary germ layer | 15/919 | 121/18723 | 8.61e-04 | 1.14e-02 | 15 |
GO:005165619 | Skin | SCCIS | establishment of organelle localization | 34/919 | 390/18723 | 8.85e-04 | 1.15e-02 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EXOC4 | SNV | Missense_Mutation | rs200509714 | c.2801N>A | p.Arg934His | p.R934H | Q96A65 | protein_coding | deleterious(0) | possibly_damaging(0.664) | TCGA-A1-A0SQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD |
EXOC4 | SNV | Missense_Mutation | rs183280115 | c.62N>T | p.Ser21Leu | p.S21L | Q96A65 | protein_coding | deleterious(0) | benign(0.444) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EXOC4 | SNV | Missense_Mutation | novel | c.1051N>T | p.Ala351Ser | p.A351S | Q96A65 | protein_coding | tolerated(0.42) | benign(0.091) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
EXOC4 | SNV | Missense_Mutation | rs183280115 | c.62N>T | p.Ser21Leu | p.S21L | Q96A65 | protein_coding | deleterious(0) | benign(0.444) | TCGA-AC-A3YI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
EXOC4 | SNV | Missense_Mutation | rs183280115 | c.62N>T | p.Ser21Leu | p.S21L | Q96A65 | protein_coding | deleterious(0) | benign(0.444) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EXOC4 | SNV | Missense_Mutation | | c.2683N>A | p.Ala895Thr | p.A895T | Q96A65 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
EXOC4 | SNV | Missense_Mutation | | c.1243N>G | p.Gln415Glu | p.Q415E | Q96A65 | protein_coding | tolerated(0.85) | benign(0.258) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
EXOC4 | SNV | Missense_Mutation | novel | c.1055N>A | p.Val352Glu | p.V352E | Q96A65 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
EXOC4 | SNV | Missense_Mutation | novel | c.1537N>T | p.Ala513Ser | p.A513S | Q96A65 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EXOC4 | insertion | Frame_Shift_Ins | novel | c.2634_2635insCCTC | p.Gln879ProfsTer30 | p.Q879Pfs*30 | Q96A65 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |